- Home
- TRIN vs GYRE Comparison
TRIN vs GYRE Comparison
Compare TRIN & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIN
- GYRE
- Stock Information
- Founded
- TRIN 2007
- GYRE 2002
- Country
- TRIN United States
- GYRE United States
- Employees
- TRIN N/A
- GYRE N/A
- Industry
- TRIN Finance/Investors Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- TRIN Finance
- GYRE Health Care
- Exchange
- TRIN Nasdaq
- GYRE Nasdaq
- Market Cap
- TRIN 912.3M
- GYRE 897.1M
- IPO Year
- TRIN 2021
- GYRE N/A
- Fundamental
- Price
- TRIN $14.16
- GYRE $8.00
- Analyst Decision
- TRIN Hold
- GYRE
- Analyst Count
- TRIN 3
- GYRE 0
- Target Price
- TRIN $14.83
- GYRE N/A
- AVG Volume (30 Days)
- TRIN 837.6K
- GYRE 204.0K
- Earning Date
- TRIN 08-06-2025
- GYRE 08-12-2025
- Dividend Yield
- TRIN 14.38%
- GYRE N/A
- EPS Growth
- TRIN 37.77
- GYRE N/A
- EPS
- TRIN 2.19
- GYRE 0.02
- Revenue
- TRIN $240,010,000.00
- GYRE $100,643,000.00
- Revenue This Year
- TRIN $24.11
- GYRE $21.04
- Revenue Next Year
- TRIN $4.87
- GYRE $89.64
- P/E Ratio
- TRIN $6.47
- GYRE $100.02
- Revenue Growth
- TRIN 30.65
- GYRE N/A
- 52 Week Low
- TRIN $12.50
- GYRE $6.11
- 52 Week High
- TRIN $16.82
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- TRIN 44.05
- GYRE 48.18
- Support Level
- TRIN $14.11
- GYRE $7.49
- Resistance Level
- TRIN $14.32
- GYRE $7.80
- Average True Range (ATR)
- TRIN 0.22
- GYRE 0.51
- MACD
- TRIN -0.01
- GYRE 0.10
- Stochastic Oscillator
- TRIN 48.72
- GYRE 64.97
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.